Associated Papers
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
40970755 (PubMed )
Supplement: crc-25-0188_supplementary_table_s5_suppst5.xlsx › Supplementary_Table_S5
In Silico Analysis of nsSNPs of Human KRAS Gene and Protein Modeling Using Bioinformatic Tools.
Xu D et al.
Acs Omega, 2023
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.
Loree JM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
Hill KS et al.
Molecular Cancer Research : Mcr, 2019
Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer.
Cheng FT et al.
Case Reports in Oncological Medicine, 2019
Mutational analysis of KRAS and its clinical implications in cervical cancer patients.
Jiang W et al.
Journal of Gynecologic Oncology, 2018
29185262 (PubMed )
Supplement: jgo-29-e4-s002.xls › jgo-29-e90-s002
KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS et al.
Annals of Surgical Oncology, 2016
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
26860319 (PubMed )
Supplement: 12859_2016_935_MOESM2_ESM.xlsx › Table_S5
Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP et al.
Annals of Surgical Oncology, 2013
Select a paper to view details